MONTREAL, Jan. 8, 2015 /PRNewswire/ -- SinSa Labs today announced the signing of a License agreement with Singapore Health Services and ETPL, A*STAR's technology transfer arm, regarding a technology developed at the Singapore Eye Research Institute (SERI) and Bioinformatics Institute (BII), A*STAR that deters the development of antibiotic resistance. This agreement provides SinSa Labs with a technology platform leading to a new class of antibiotics that kill bacteria quickly at a low dose and deters antibiotic resistance.
Currently the company is developing its first antibiotic (Dorzidin™) suitable for treating antibiotic-resistant eye and ear infections. SinSa Labs is seeking series A financing, as will be outlined in an offer to invest.
Professor Roger Beuerman, SinSa's co-founder and leader of the research team behind the new class of antibiotics, said, "It is exciting and promising that this scientific research will be commercialized by SinSa Labs and made available to patients. Many lives can be saved."
According to the U.S. Food and Drug Administration (FDA), "almost all important bacterial infections in the United States and throughout the world are becoming resistant to antibiotics". (www.fda.gov). With Sinsa Labs' SpearHead Technology (SHT) it is possible to counteract this bleak future.
SinSa Labs is developing the SpearHead Technology, using bioengineered molecules to penetrate and breakdown the membrane of the bacteria. With this technique both Gram-negative and Gram-positive bacteria are rapidly killed. SHT antibiotics are powerful antibiotics on their own. In addition, some SHT antibiotics at very low concentrations work synergistically with traditional antibiotics, thereby increasing the therapeutic window and decreasing the amount of antibiotic substance used.
For further information please visit www.sinsalabs.com
SOURCE SinSa Labs